Publications
Detailed Information
PCI시술시 혈소판 당단백 GP IIb/IIIA 억제제(Abciximab) 투여의 경제적 가치 : Economic Value of Platelet Glycoprotein IIb/IIIA Receptor Blocker (Abciximab) for Percutaneous Coronary Intervention
Cited 0 time in
Web of Science
Cited 0 time in Scopus
- Authors
- Issue Date
- 2007
- Citation
- 약학회지 51, 3 (2007)
- Keywords
- abciximab ; cost-effectiveness analysis ; cost-benefit analysis ; PCI
- Abstract
- This study was performed to analyse the economic value of abciximab which is used in PCI to prevent high-risk patients with ischemic complications. The effectiveness of abciximab was extracted from published clinical trials by search-ing CCIS, and the direct medical costs relevant to using abciximab were estimated from the NHI claims database. The results in terms of cost per life-year gained (LYG) and cost per QALY gained showed that abciximab was cost-effective enough to deserve its cost. Social net benefit resulting from abciximab in PCI was estimated to be 60-70 billion Won per year
- ISSN
- 0377-9556
- Language
- Korean
- Files in This Item:
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.